Pfizer (PFE) said Saturday that its investigational drug sasanlimab in combination with standard of care Bacillus Calmette-Guerin as induction and maintenance therapy in patients with high-risk non-muscle invasive bladder cancer met its primary endpoint of event-free survival in a phase 3 trial.
The trial showed a 32% reduction in the risk of disease-related events with the sasanlimab combination regimen as compared with the standard of care treatment alone, the pharmaceutircal giant said.
The probability of being event-free at 36 months was 82.1% with sasanlimab in combination with BCG and 74.8% with BCG alone, the company said.
Sasanlimab in combination with induction-only BCG failed to meet a secondary endpoint of prolongation of event-free survival compared with BCG alone as an induction and maintenance therapy, the company said.
Pfizer said it has shared study data with health authorities worldwide to support potential regulatory filings.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。